Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5840385 | 1.00 | MAPT (0.44) | MAPTPKMKDM4ECHEK1CHEK2 | |
| SCHEMBL5840247 | 0.81 | USP30 (0.43) | SLC6A3SLC18A2ALDH1A1 | |
| SCHEMBL26818738 | 0.73 | MAPT (0.76) | MAPTPKMALDH1A1LMNAHTT | |
| SCHEMBL7887174 | 0.73 | MAPT (0.76) | MAPTPKMALDH1A1LMNAHTT | |
| SCHEMBL3552839 | 0.73 | MAPT (0.76) | MAPTPKMALDH1A1LMNAHTT | |
| Hydrochloric Acid SCHEMBL5839304 | 0.72 | MAPT (0.78) | MAPTPKMALDH1A1LMNAHTT | |
| SCHEMBL5840377 | 0.71 | L3MBTL1 (0.53) | MAPTPKM | |
| SCHEMBL5805919 | 0.67 | CHRM2 (0.44) | PKMKDM4E | |
| SCHEMBL31449926 | 0.67 | MAPT (0.52) | MAPTPKMKDM4EALDH1A1LMNA | |
| SCHEMBL7214703 | 0.66 | MAPT (0.51) | MAPTPKMKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138423-B2 | Diseases mediated by tachykinins and for seritonin reuptake transporter protein as reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | BRISTOL-MEYERS SQUIBB COMPANY | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020011-A1 | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists | TPH1, SLC6A4, HTR1D | MAPT 2859/4885PKM 129/4885KDM4E 1558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.